The DOI matches its Crossref record.
Recovery of N-acetylaspartate in corticomotor neurons of patients with ALS after riluzole therapy
Abstract
Riluzole, a glutamate antagonist, has been shown to be efficacious in the treatment of patients with amyotrophic lateral sclerosis (ALS), allowing prolonged survival and time to tracheostomy. The efficacy of riluzole in thought to result from reduced glutamate excitotoxicity on motor neurons of patients with ALS, but this has never been demonstrated directly in vivo. N-acetylaspartate (NAA), a compound that is readily measured in vivo using proton magnetic resonance spectroscopy, can be used as a surrogate marker for neuronal loss or sublethal injury. To determine whether riluzole reverses sublethal corticomotoneuron damage in patients with ALS we measured NAA/creatine (Cr) relative intensity ratios in the motor cortex before and after treatment with riluzole 50 mg bid. After 3 weeks of riluzole therapy in 11 patients NAA/Cr increased from 2.14 +/- 0.26 to 2.27 +/- 0.24 (p = 0.044), whereas, in 12 untreated patients NAA/Cr decreased from 2.17 +/- 0.20 to 2.08 +/- 0.20 (p = 0.099). Thus the change in NAA/Cr between the treated and untreated groups was 0.22 +/- 0.095 (p = 0.008). The magnitude of increase in NAA/Cr in those treated was not correlated with age, sex, duration of treatment or disease, the presence of probable or definite upper motor neuron (UMN) signs, bulbar features, or pre-treatment NAA/Cr. We conclude that magnetic resonance spectroscopy can provide a novel surrogate measure of neuronal integrity that demonstrates reversal of sublethal UMN injury in patients with ALS within weeks of initiating riluzole therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND)
Miller, R., Mitchell, J., Lyon, M., & Moore, D. (2002) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001447 · Cited by 909
Biomarkers in amyotrophic lateral sclerosis
Turner, M. R., Kiernan, M. C., Leigh, P. N., & Talbot, K. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70293-x · Cited by 438
Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND)
Miller, R. G., Mitchell, J. D., Lyon, M., & Moore, D. H. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001447.pub2 · Cited by 313
Steen, R. G., Hamer, R. M., & Lieberman, J. A. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300850 · Cited by 254
Decreased hippocampal N-acetylaspartate in the absence of atrophy in posttraumatic stress disorder
Schuff, N., Neylan, T. C., Lenoci, M. A., Du, A.-T., Weiss, D. S., Marmar, C. R., & Weiner, M. W. (2001) · Biological Psychiatry · doi:10.1016/s0006-3223(01)01245-8 · Cited by 237
Metadata
- Authors
- Kalra, S., Cashman, N. R., Genge, A., & Arnold, D. L.
- Venue
- NeuroReport
- Published
- 1998-06
- Volume
- 9
- Issue
- 8
- Pages
- 1757-1761
- ISSN
- 0959-4965 (ISSN-L)
- OpenAlex
- W2027290785
- Cited by
- 178
- References
- 0
- FWCI
- 9.86
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Recovery of N-acetylaspartate in corticomotor neurons of patients with ALS after riluzole therapy. https://app.cochat.ai/papers/10.1097/00001756-199806010-00016
- The paper
- Kalra, S., Cashman, N. R., Genge, A., & Arnold, D. L. (1998). Recovery of N-acetylaspartate in corticomotor neurons of patients with ALS after riluzole therapy. NeuroReport. https://doi.org/10.1097/00001756-199806010-00016
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.